Pfizer’s (PFE) “Buy” Rating Reaffirmed at Guggenheim

Pfizer (NYSE:PFE)‘s stock had its “buy” rating restated by equities researchers at Guggenheim in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $33.00 target price on the biopharmaceutical company’s stock. Guggenheim’s target price indicates a potential upside of 28.13% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. Wolfe Research began coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Pfizer has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Stock Performance

NYSE:PFE opened at $25.76 on Monday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a 50 day simple moving average of $26.28 and a two-hundred day simple moving average of $27.72. The company has a market capitalization of $145.96 billion, a PE ratio of 18.27, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.10 earnings per share. Research analysts anticipate that Pfizer will post 2.95 earnings per share for the current year.

Institutional Trading of Pfizer

Several institutional investors have recently made changes to their positions in PFE. Retirement Wealth Solutions LLC purchased a new position in Pfizer in the fourth quarter worth $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer in the 4th quarter worth about $26,000. Gladius Capital Management LP grew its position in Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 38,015 shares during the period. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer during the fourth quarter worth about $28,000. Finally, Noble Wealth Management PBC bought a new stake in Pfizer in the fourth quarter worth about $31,000. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.